BRAF p.V600E

About

Gene context: BRAF

Biomarker Type: Somatic Variant

Present: True

Chromosome: 7

Start Position: 140453136

End Position: 140453136

Reference Allele: A

Alternate Allele: T

Cdna Change: c.1799T>A

Protein Change: p.V600E

Variant Annotation: Missense

Exon: 15

Rsid: rs113488022

Hgvsg: 7:g.140453136A>T


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
EMA (2) FDA (2) BRAF p.V600E Melanoma Binimetinib, Encorafenib
EMA (2) FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
EMA (1) FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
EMA (1) FDA (1) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
EMA (1) FDA (1) BRAF p.V600E Melanoma Dabrafenib
EMA (4) FDA (4) BRAF p.V600E Melanoma Dabrafenib, Trametinib
EMA (2) FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Anaplastic Thyroid Cancer Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Any solid tumor Dabrafenib, Trametinib
EMA (1) FDA (2) BRAF p.V600E Low-Grade Glioma, NOS Dabrafenib, Trametinib
EMA (1) FDA (1) BRAF p.V600E Melanoma Trametinib
EMA (1) FDA (1) BRAF p.V600E Melanoma Vemurafenib
FDA (1) BRAF p.V600E Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
FDA (1) BRAF p.V600E Low-Grade Glioma, NOS Tovorafenib
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
EMA (1) BRAF p.V600E High-Grade Glioma, NOS Dabrafenib, Trametinib
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan